Sidra Medicine to deliver first CRISPR gene therapy
Sidra Medicine in Qatar has become the first hospital in the country to administer Casgevy, a revolutionary gene therapy using CRISPR/Cas9 technology to treat inherited blood disorders. The therapy is available for patients aged 12 and above with transfusion-dependent beta thalassemia and severe sickle cell disease.
Sidra Medicine has become the first hospital in Qatar to administer Casgevy, a gene therapy that uses CRISPR/Cas9 technology to treat inherited blood disorders. Casgevy is available for patients aged 12 and above with transfusion-dependent beta thalassemia and severe sickle cell disease. The therapy has been approved by the Ministry of Public Health in Qatar and other international agencies. Sidra Medicine currently follows around 150-200 children in Qatar diagnosed with thalassemia and sickle cell disease. The hospital has already onboarded its first patient for assessment. Casgevy offers the potential for a functional cure by addressing these diseases at their genetic origin.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.